Literature DB >> 20093238

Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis.

Yosuke Matsumoto1, Shigeo Horiike, Muneo Ohshiro, Mio Yamamoto, Nana Sasaki, Yasuhiko Tsutsumi, Tsutomu Kobayashi, Daisuke Shimizu, Hitoji Uchiyama, Junya Kuroda, Kenichi Nomura, Chihiro Shimazaki, Masafumi Taniwaki.   

Abstract

The normal counterparts of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have not been accurately identified. We immunohistochemically analyzed 10 PTCL-NOS cases to examine the expression of the master regulators of T-cell differentiation and of surface antigens, including chemokine receptors. All cases were positive for the master regulator of helper T cells (Th-POK) and the marker of effector T cells (CD45RO). Three cases each were positive for T-Bet and GATA3, which are master regulators of helper T cells (T(H) ) type 1 (T(H)1) and 2 (T(H)2), respectively. Two cases were positive for the surface antigens of central memory (Tcm) (CCR7 and CD62L), and 1 case was positive for follicular helper T-cell (TFH) phenotype (BCL6, CXCL13, and PD-1). The remaining case was negative for all markers of effector T(H) subtypes. These results suggest the postulated normal counterparts of PTCL-NOS identified in 9 of the 10 cases consist of T(H)1, T(H)2, TCM, and TFH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093238     DOI: 10.1309/AJCP0SBHYVLY5EML

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Inflammatory cells of immunosuppressive phenotypes in oral lichen planus have a proinflammatory pattern of expression and are associated with clinical parameters.

Authors:  Marilena Vered; Eran Fürth; Yifat Shalev; Dan Dayan
Journal:  Clin Oral Investig       Date:  2012-08-15       Impact factor: 3.573

2.  Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma.

Authors:  Yosuke Matsumoto; Hisao Nagoshi; Mihoko Yoshida; Seiichi Kato; Junya Kuroda; Kazuho Shimura; Hiroto Kaneko; Shigeo Horiike; Shigeo Nakamura; Masafumi Taniwaki
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

3.  GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma.

Authors:  Wei Zhang; Zi Wang; Yunping Luo; Dingrong Zhong; Yufeng Luo; Daobin Zhou
Journal:  Oncotarget       Date:  2016-10-04

4.  Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.

Authors:  Rebeca Manso; Julia González-Rincón; Manuel Rodríguez-Justo; Giovanna Roncador; Sagrario Gómez; Margarita Sánchez-Beato; Miguel A Piris; Socorro M Rodríguez-Pinilla
Journal:  Oncotarget       Date:  2018-03-01

Review 5.  Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Authors:  Masafumi Taniwaki; Mihoko Yoshida; Yosuke Matsumoto; Kazuho Shimura; Junya Kuroda; Hiroto Kaneko
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-02-15       Impact factor: 2.576

Review 6.  The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).

Authors:  Helen Ma; Ardy Davarifar; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 4.213

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.